The short version of CJC-1295 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-05. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
=== Advantages === In the early 1970s, the Alza Corporation, through their founder Alejandro Zaffaroni, filed the first US patents describing transdermal delivery systems for scopolamine, nitroglycerin and nicotine. People found that applying medicines on the body surfaces is beneficial in many aspects. Skin medicines can give faster onset and local effect on our body as the surface cream can bypass first pass metabolism such as hepatic and intestinal metabolism. Apart from the absorption, dermal drugs effectively prevent oral delivery limitations such as nausea and vomiting and poor appliances due to unpalatable tastes of the drugs . Topical application is an easy way for patients to tackle skin infections in a painless and non-invasive way. From a patient perspective, applying drugs on skin also provides stable dosage in blood so as to give the optimal bioavailability and therapeutic effects. In case of overdose or unwanted side effects, patients can take off or wash out the medicines quickly to eliminate toxicity by simply removing the patch to stop the delivery of drugs.
== Monitoring and improvement == Stewardship programs use laboratory utilization data to identify opportunities for improvement and evaluate interventions. Monitoring may include the appropriateness of test orders, retrieval of results, interpretation of results, test volumes, costs, and the effects of individual interventions. Broader measures of impact may include blood collection volumes, length of stay, readmission, morbidity, and mortality. Data-driven approaches can also use implementation science to identify behavioral and organizational factors that influence laboratory test use and to select interventions suited to those factors. Laboratory stewardship programs use multidisciplinary teams and laboratory utilization data to identify inappropriate testing and opportunities for improvement, implement interventions, and assess their effects. Programs can be organized differently depending on institutional priorities, available resources, and the clinical setting. Laboratory stewardship has also been discussed as a means of addressing health equity in laboratory testing.
== Ion source dependence == The ionization techniques available for MSI are suited to different applications. Some of the criteria for choosing the ionization method are the sample preparation requirement and the parameters of the measurement, as resolution, mass range and sensitivity. Based on that, the most common used ionization method are MALDI, SIMS AND DESI which are described below. Still, other minor techniques used are laser ablation electrospray ionization (LAESI), laser-ablation-inductively coupled plasma (LA-ICP) and nanospray desorption electrospray ionization (nano-DESI).
== External links == Images of fruit development from flowers at bioimages.Vanderbilt.edu (archived 18 February 2007) Fruit and seed dispersal images at bioimages.Vanderbilt.edu (archived 25 April 2017) Fruit Facts (Archived 2020-07-12 at the Wayback Machine from California Rare Fruit Growers, Inc.) Photo ID of Fruits (Archived 2021-01-09 at the Wayback Machine by Capt. Pawanexh Kohli) "Fruit" . Encyclopædia Britannica (11th ed.). 1911.
Sources: en.wikipedia.org
The endothelial cells retract and the leukocytes pass through the basement membrane into the surrounding tissue using adhesion molecules such as ICAM-1. Movement of leukocytes within the tissue via chemotaxis: Leukocytes reaching the tissue interstitium bind to extracellular matrix proteins via expressed integrins and CD44 to prevent them from leaving the site. A variety of molecules behave as chemoattractants, for example, C3a or C5a (the anaphylatoxins), and cause the leukocytes to move along a chemotactic gradient towards the source of inflammation.
The aromatic acids 3-phenylpropionic acid (3PPA) and 3-(4-hydroxyphenyl)propionic acid (HPPA) are important commodities used in the chemical, pharmaceutical, and food industrial sectors. A biosynthetic route to synthetize these compounds was designed by combining the Escherichia coli phenylalanine pathway with non-native enzymes like tyrosine ammonia lyase (TAL) and the clostridial EnoR. The full pathway was assembled in Escherichia coli, which led to the production of HPPA and cinnamyl alcohol. Optimization of individual enzyme expression levels produced 3PPA and HPPA with a concentration of 367 and 225 mg/L, in this case the oxygen-sensitive EnoRs were catalytically active under the microaerophilic fermentation conditions. The 2-methylsuccinic acid (2-MSA) is used to synthetize polymers that have application as bioplastics, cosmetic solvents and coatings. A pathway for its synthesis was designed using Escherichia coli, combining native pyruvate and acetyl-CoA biosynthesis with methanogenic citramalate synthase (CimA), isopropylmalate isomerase (LeuCD), and the ER YqjM or KpnER from Klebsiella pneumoniae. The successful production of 2-MSA was achieved with a concentration of 0.96 g/L using KpnER.
The term thagomizer was coined by Gary Larson in jest. In a 1982 The Far Side comic, a group of cavemen are taught by a caveman lecturer that the spikes on a stegosaur's tail were named "after the late Thag Simmons". The term was picked up initially by Kenneth Carpenter, then a paleontologist at the Denver Museum of Nature and Science, who used the term when describing a fossil at the Society of Vertebrate Paleontology Annual Meeting in 1993. Thagomizer has since been adopted as an anatomical term and is used by the Smithsonian Institution, the Dinosaur National Monument, the book The Complete Dinosaur and the BBC documentary series Planet Dinosaur. The term has also appeared in some scientific papers describing stegosaurs and related dinosaurs.
Sources: en.wikipedia.org
==== Increasing mandatory tests in California ==== Many rare diseases have not historically been tested for or testing that has been available has not been mandatory. One such disease is glutaric acidemia type I, a neurometabolic disease present in approximately 1 out of every 100,000 live births. A short-term California testing pilot project in 2003 and 2004 demonstrated the cost of forgoing rare disease testing on newborns. While both Zachary Wyvill and Zachary Black were both born with the same disease during the pilot program, Wyvill's birth hospital tested only for four state-mandated diseases while Black was born at a hospital participating in the pilot program. Wyvill's disease went undetected for over six months during which irreversible damage occurred but Black's disease was treated with diet and vitamin supplements. Both sets of parents became advocates for expanded neonatal testing and testified in favor of expanding tandem mass spectrometry (MS/MS) testing of newborns for rare diseases. By August, 2004, the California state budget law had passed requiring the use of tandem mass spectroscopy to test for more than 30 genetic illnesses and provided funding. California now mandates newborn screening for all infants and tests for 80 congenital and genetic disorders.
== History == In May 2023, the China Manned Space Agency (CMSA) issued a public solicitation for proposals for a low-cost cargo transportation system. Key requirements included an upmass capacity of at least 1.8 tonnes (1.8 long tons; 2.0 short tons), a pressurized volume of at least 7 cubic metres (250 cu ft), the ability to remain docked for at least three months, a waste disposal capacity of at least 2 tonnes (2.0 long tons; 2.2 short tons), and a target cost of no more than 120 million RMB per ton. In September 2023, IAMCAS's proposal was selected as one of the four finalists from ten submissions. By October 2024, the CMSA announced that the Qingzhou spacecraft and the Haolong cargo spaceplane (developed by the Chengdu Aircraft Design Institute) had won the final competition and were awarded contracts for flight verification. On 30 March 2026, a prototype version of Qingzhou was launched on the maiden flight of CAS Space's Kinetica 2.
== Society and culture == The altered appearance caused by vitiligo can affect a person's emotional and psychological well-being. It may lead to employment difficulties, particularly if vitiligo develops on visible areas of the body, such as the face, hands, or arms. Participating in a vitiligo support group may improve social coping skills and emotional resilience.
The vocalisations of emus mostly consist of various booming and grunting sounds. The booming is created by the inflatable throat pouch; the pitch can be regulated by the bird and depends on the size of the aperture. Most of the booming is done by females; it is part of the courtship ritual, is used to announce the holding of territory and is issued as a threat to rivals. A high-intensity boom is audible 2 kilometres (1.2 mi) away, while a low, more resonant call, produced during the breeding season, may at first attract mates and peaks while the male is incubating the eggs. Most of the grunting is done by males. It is used principally during the breeding season in territorial defence, as a threat to other males, during courtship and while the female is laying. Both sexes sometimes boom or grunt during threat displays or on encountering strange objects. On very hot days, emus pant to maintain their body temperature. Their lungs work as evaporative coolers and, unlike some other species, the resulting low levels of carbon dioxide in the blood do not appear to cause alkalosis. For normal breathing in cooler weather, they have large, multifolded nasal passages. Cool air warms as it passes through into the lungs, extracting heat from the nasal region. On exhalation, the emu's cold nasal turbinates condense moisture back out of the air and absorb it for reuse. As with other ratites, the emu has great homeothermic ability, and can maintain this status from −5 to 45 °C (23 to 113 °F). The thermoneutral zone of emus lies between 10 and 30 °C (50 and 86 °F).
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.